Joris Verlooy

Dr. Joris Verlooy


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2019 in Cancers
Verified
Journal Article
Open access
PDF file
SBSévérine de Bruijn
Sévérine de Bruijn
SASébastien Anguille
Sébastien Anguille
JVJoris Verlooy
Joris Verlooy
ESEvelien Smits
Evelien Smits
VTViggo Van Tendeloo
Viggo Van Tendeloo
ELEva Lion
Eva Lion
Dendritic cell-based and other vaccination strategies that use the patient’s own immune system for the treatment of cancer are gaining momentum. Most studies of therapeutic cancer vaccination have been performed in adults. However, since cancer is one of the leading causes of death among children past infancy in the Western world, the hope is that this form of active specific immunotherapy can play an important role in the pediatric population as well. Since children have more vigorous and adaptable immune systems than adults, therapeutic cancer vaccines are expected to have a better chance of creating protective immunity and preventing cancer recurrence in pediatric patients. Moreover, in contrast to conventional cancer treatments such as chemotherapy, therapeutic cancer vaccines are designed to specifically target tumor cells and not healthy cells or tissues. This reduces the likelihood of side effects, which is an important asset in this vulnerable patient population. In this review, we present an overview of the different therapeutic cancer vaccines that have been studied in the pediatric population, with a main focus on dendritic cell-based strategies. In addition, new approaches that are currently being investigated in clinical trials are discussed to provide guidance for further improvement and optimization of pediatric cancer vaccines.

29 January 2025 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
ADAnne van Driessche
Anne van Driessche
JCJoachim Cohen
Joachim Cohen
LDLuc Deliens
Luc Deliens
MKMarijke C. Kars
Marijke C. Kars
LWLeen Willems
Leen Willems
KBKim Beernaert
Kim Beernaert

27 October 2025 in Academia Oncology
Verified
Journal Article
Open access
PDF file
FJFlore Janssens
Flore Janssens
PMPaul Meijnders
Paul Meijnders
JVJoris Verlooy
Joris Verlooy
The survival rates for childhood and adolescent cancer have improved significantly over recent decades, with the five-year survival now exceeding 80% in many regions. However, cancer therapies, while lifesaving, are associated with late effects, or health complications that emerge months to years after treatment. These effects, which include physical, psychological, and cognitive issues, affect over 60% of survivors and often persist or worsen with age. Common late effects involve the cardiovascular, endocrine, and musculoskeletal systems, as well as neurocognitive impairment, infertility, and the risk of subsequent malignancies. Long-term follow-up (LTFU) care is critical for identifying and managing these conditions. Risk-based, individualized LTFU can enhance survivors’ health awareness, promote timely interventions, and improve quality of life. Guidelines from international organizations like PanCare and the International Guideline Harmonization Group support structured, evidence-based care pathways. Nurse-led models for the organization of LTFU are emerging as effective and patient-centered approaches within multidisciplinary teams. Despite its importance, LTFU participation remains suboptimal. Survivorship care plans and improved communication may help increase engagement. As therapies evolve, personalized follow-up strategies based on treatment history and risk profiling will be essential. This narrative review article explores the prevalence and burden of late effects; highlights the role of LTFU; and examines future directions for optimizing survivorship care in childhood and adolescent cancer survivors.